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TIP 63 MEDICATIONS FOR OPIOID USE DISORDER
Executive Summary 
For Healthcare and Addiction Professionals, Policymakers, Patients, and Families 
The Executive Summary of this Treatment Improvement Protocol provides an overview on the 
use of the three Food and Drug Administration-approved medications used to treat opioid use 
disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services 
needed to support recovery. 
TIP Navigation 
Executive Summary 
For healthcare and addiction professionals, policymakers, patients, and families 
Part 1: Introduction to Medications for Opioid Use Disorder Treatment 
For healthcare and addiction professionals, policymakers, patients, and families 
Part 2: Addressing Opioid Use Disorder in General Medical Settings 
For healthcare professionals 
Part 3: Pharmacotherapy for Opioid Use Disorder 
For healthcare professionals 
Part 4: Partnering Addiction Treatment Counselors With Clients and Healthcare Professionals 
For healthcare and addiction professionals 
Part 5: Resources Related to Medications for Opioid Use Disorder 
For healthcare and addiction professionals, policymakers, patients, and families 
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Foreword 
The Substance Abuse and Mental Health Services Administration (SAMHSA) is the U.S. Department of 
Health and Human Services agency that leads public health efforts to advance the behavioral health 
of the nation. SAMHSA’s mission is to reduce the impact of substance abuse and mental illness on 
America’s communities. 
The Treatment Improvement Protocol (TIP) series fulflls SAMHSA’s mission by providing science-
based best-practice guidance to the behavioral health feld. TIPs refect careful consideration of all 
relevant clinical and health service research, demonstrated experience, and implementation require-
ments. Select nonfederal clinical researchers, service providers, program administrators, and patient 
advocates comprising each TIP’s consensus panel discuss these factors, offering input on the TIP’s 
specifc topic in their areas of expertise to reach consensus on best practices. Field reviewers then 
assess draft content. 
The talent, dedication, and hard work that TIP panelists and reviewers bring to this highly participatory 
process have helped bridge the gap between the promise of research and the needs of practicing 
clinicians and administrators to serve, in the most scientifcally sound and effective ways, people in 
need of behavioral health services. We are grateful to all who have joined with us to contribute to 
advances in the behavioral health feld. 
Elinore F. McCance-Katz, M.D., Ph.D. 
Assistant Secretary for Mental Health and Substance Use 
SAMHSA 
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Acting Director 
Center for Substance 
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Estimated cost
of the OPIOID
EPIDEMIC was 
$504 
BILL ION
in 2015.2 
 An estimated 1.8M
AMERICANS 
have OUD related to 
opioid painkillers; 
626K have heroin-
related OUD.3 
 
 
 
 
  
  
Executive Summary 
The goal of treatment for opioid addiction or opioid use disorder (OUD) is remission of the 
disorder leading to lasting recovery. Recovery is a process of change through which individ-
uals improve their health and wellness, live self-directed lives, and strive to reach their full 
potential.1 This Treatment Improvement Protocol (TIP) reviews the use of the three Food 
and Drug Administration (FDA)-approved medications used to treat OUD—methadone, 
naltrexone, and buprenorphine—and the other strategies and services needed to support 
recovery for people with OUD. 
Introduction 
Our nation faces a crisis of overdose deaths from 
opioids, including heroin, illicit fentanyl, and 
prescription opioids. These deaths represent a 
mere fraction of the total number of Americans 
harmed by opioid misuse and addiction. Many 
Americans now suffer daily from a chronic 
medical illness called “opioid addiction” or 
OUD (see the Glossary in Part 5 of this TIP for 
defnitions). Healthcare professionals, treatment 
providers, and policymakers have a responsibility 
to expand access to evidence-based, effective 
care for people with OUD. The TIP is divided into parts so that readers can 
easily fnd the material they need. Part 1 is a
general introduction to providing medications 
for OUD and issues related to providing that
treatment. Some readers may prefer to go directly
to those parts most relevant to their areas of
interest, but everyone is encouraged to read
Part 1 to establish a shared understanding of
key facts and issues covered in detail in this TIP. 
Following is a summary of the TIP’s overall main 
points and brief summaries of each of the fve 
TIP parts. 
An expert panel developed the TIP’s content 
based on a review of the literature and on their 
extensive experience in the feld of addiction 
treatment. Other professionals also generously 
contributed their time and commitment to this 
project. 
Overall Key Messages 
Addiction is a chronic, treatable illness. 
Opioid addiction, which generally corresponds 
with moderate to severe forms of OUD, often 
requires continuing care for effective treatment 
rather than an episodic, acute-care treatment 
approach. 
 Opioid overdose caused 
42,249 DEATHS 
nationwide in 2016— 
this exceeded the #
caused by motor vehicle 
crashes.4,5 
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General principles of good care for chronic 
diseases can guide OUD treatment. 
Approaching OUD as a chronic illness can 
help providers deliver care that helps patients 
stabilize, achieve remission of symptoms, and 
establish and maintain recovery. 
Patient-centered care empowers patients 
with information that helps them make better 
treatment decisions with the healthcare 
professionals involved in their care. Patients 
should receive information from their healthcare 
team that will help them understand OUD and 
the options for treating it, including treatment 
with FDA-approved medication. 
Patients with OUD should have access to 
mental health services as needed, medical 
care, and addiction counseling, as well as 
recovery support services, to supplement 
treatment with medication. 
The words you use to describe OUD and 
an individual with OUD are powerful. The 
TIP defnes, uses, and encourages providers 
to adopt terminology that will not reinforce 
prejudice, negative attitudes, or discrimination. 
There is no “one size fts all” approach to 
OUD treatment. Many people with OUD beneft 
from treatment with medication for varying 
lengths of time, including lifelong treatment. 
Ongoing outpatient medication treatment for 
OUD is linked to better retention and outcomes 
Medications for Opioid Use Disorder 
than treatment without medication. Even so, 
some people stop using opioids on their own; 
others recover through support groups or 
specialty treatment with or without medication. 
The science demonstrating the effectiveness 
of medication for OUD is strong. For example, 
methadone, extended-release injectable naltrex-
one (XR-NTX), and buprenorphine were each 
found to be more effective in reducing illicit 
opioid use than no medication in randomized 
clinical trials, which are the gold standard for 
demonstrating effcacy in clinical medicine.6,7,8,9,10 
Methadone and buprenorphine treatment 
have also been associated with reduced risk of 
overdose death.11,12,13,14,15 
This doesn’t mean that remission and recovery 
occur only through medication. Some people 
achieve remission without OUD medication, just 
as some people can manage type 2 diabetes 
with exercise and diet alone. But just as it is 
inadvisable to deny people with diabetes the 
medication they need to help manage their 
illness, it is also not sound medical practice to 
deny people with OUD access to FDA-approved 
medications for their illness. 
Medication for OUD should be successfully 
integrated with outpatient and residential 
treatment. Some patients may beneft from 
different levels of care at different points in their 
lives, such as outpatient counseling, intensive 
outpatient treatment, inpatient treatment, or 
long-term therapeutic communities. Patients 
treated in these settings should have access to 
OUD medications. 
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2.1 MILLION 
people in the U.S.,
ages 12 and older, 
had OUD involving
PRESCRIPTION 
OPIOIDS, HEROIN, 
or both in 2016.16 
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Patients treated with medications for OUD 
can beneft from individualized psychosocial 
supports. These can be offered by patients’ 
healthcare providers in the form of medication 
management and supportive counseling and/or 
by other providers offering adjunctive addiction 
counseling, recovery coaching, mental health 
services, and other services that may be needed 
by particular patients. 
Expanding access to OUD medications is 
an important public health strategy.17 The 
gap between the number of people needing 
opioid addiction treatment and the capacity to 
treat them with OUD medication is substantial. 
In 2012, the gap was estimated at nearly 1 
million people, with about 80 percent of opioid 
treatment programs (OTPs) nationally operating 
at 80 percent capacity or greater.18 
Improving access to treatment with OUD 
medications is crucial to closing the wide 
gap between treatment need and treatment 
availability, given the strong evidence of 
effectiveness for such treatments.19 
Data indicate that medications for OUD are 
cost effective and cost benefcial.20,21 
OPIOID-RELATED 
EMERGENCY 
DEPARTMENT 
visits nearly doubled 
from 2005–2014.22 
Executive Summary 
Content Overview 
The TIP is divided into parts to make the material 
more accessible according to the reader’s interests. 
Part 1: Introduction to Medications for 
Opioid Use Disorder Treatment 
This part lays the groundwork for understanding 
treatment concepts discussed later in this TIP. 
The intended audience includes: 
• Healthcare professionals (physicians, nurse
practitioners, physician assistants, and nurses).
• Professionals who offer addiction counseling
or mental health services.
• Peer support specialists.
• People needing treatment and their families.
• People in remission or recovery and their
families.
• Hospital administrators.
• Policymakers.
In Part 1, readers will learn that: 
• Increasing opioid overdose deaths, illicit
opioid use, and prescription opioid misuse
constitute a public health crisis.
• OUD medications reduce illicit opioid use,
retain people in treatment, and reduce risk of
opioid overdose death better than treatment
with placebo or no medication.
• Only physicians, nurse practitioners, and
physician assistants can prescribe buprenor-
phine for OUD. They must get a federal
waiver to do so.
• Only federally certifed, accredited OTPs can
dispense methadone to treat OUD. OTPs
can administer and dispense buprenorphine
without a federal waiver.
• Any prescriber can offer naltrexone.
• OUD medication can be taken on a short- or
long-term basis, including as part of medically
supervised withdrawal and as maintenance
treatment.
• Patients taking medication for OUD are
considered to be in recovery.
• Several barriers contribute to the underuse of
medication for OUD.
Part 2: Addressing Opioid Use Disorder in 
General Medical Settings 
This part offers guidance on OUD screening, 
assessment, treatment, and referral. Part 2 is 
for healthcare professionals working in general 
medical settings with patients who have or are 
at risk for OUD. 
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inpatient hospital stays 
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nationally from 2005–2014.24 
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In Part 2, readers will learn that: 
• All healthcare practices should screen for
alcohol, tobacco, and other substance misuse
(including opioid misuse).
• Validated screening tools, symptom surveys,
and other resources are readily available; this
part lists many of them.
• When patients screen positive for risk of harm
from substance use, practitioners should
assess them using tools that determine
whether substance use meets diagnostic
criteria for a substance use disorder (SUD).
• Thorough assessment should address
patients’ medical, social, SUD, and family
histories.
• Laboratory tests can inform treatment
planning.
• Practitioners should develop treatment plans
or referral strategies (if onsite SUD treatment
is unavailable) for patients who need SUD
treatment.
Part 3: Pharmacotherapy for Opioid Use 
Disorder 
This part offers information and tools for health-
care professionals who prescribe, administer, 
or dispense OUD medications or treat other 
illnesses in patients who take these medications. 
It provides guidance on the use of buprenorphine,
methadone, and naltrexone by healthcare
professionals in: 
• General medical settings, including hospitals.
• Offce-based opioid treatment settings.
• Specialty addiction treatment programs,
including OTPs.
In Part 3, readers will learn that: 
• OUD medications are safe and effective when
used appropriately.
• OUD medications can help patients reduce or
stop illicit opioid use and improve their health
and functioning.
• Pharmacotherapy should be considered for all
patients with OUD. Opioid pharmacothera-
pies should be reserved for those with moder-
ate-to-severe OUD with physical dependence.
• Patients with OUD should be informed of
the risks and benefts of pharmacotherapy,
treatment without medication, and no
treatment.
• Patients should be advised on where and how
to get treatment with OUD medication.
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OPIOID ADDICTION 
is linked with high rates of 
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• Doses and schedules of pharmacotherapy
must be individualized.
Part 4: Partnering Addiction Treatment 
Counselors With Clients and Healthcare 
Professionals 
This part recommends ways that addiction 
treatment counselors can collaborate with 
healthcare professionals to support client-
centered, trauma-informed OUD treatment 
and recovery. It also serves as a quick guide to 
medications that can treat OUD and presents 
strategies for clear communication with pre-
scribers, creation of supportive environments 
for clients who take OUD medication, and ways 
to address other common counseling concerns 
when working with this population. 
In Part 4, readers will learn that: 
• Many patients taking OUD medication beneft
from counseling as part of treatment.
• Counselors play the same role for clients with
OUD who take medication as for clients with
any other SUD.
• Counselors help clients recover by addressing
the challenges and consequences of addiction.
• OUD is often a chronic illness requiring
ongoing communication among patients and
providers to ensure that patients fully beneft
from both pharmacotherapy and psychosocial
treatment and support.
• OUD medications are safe and effective when
prescribed and taken appropriately.
• Medication is integral to recovery for many
people with OUD. Medication usually
produces better treatment outcomes than
outpatient treatment without medication.
• Supportive counseling environments for
clients who take OUD medication can
promote treatment and help build recovery
capital.
Part 5: Resources Related to Medications 
for Opioid Use Disorder 
This part has a glossary and audience-segmented 
resource lists to help medical and behavioral 
health service providers better understand how 
to use OUD medications with their patients and 
to help patients better understand how OUD 
medications work. It is for all interested readers. 
In Part 5, readers will learn that: 
• Practice guidelines and decision-making tools
can help healthcare professionals with OUD
screening, assessment, diagnosis, treatment
planning, and referral.
• Patient- and family-oriented resources provide
information about opioid addiction in general;
the role of medication, behavioral and sup-
portive services, and mutual-help groups in
the treatment of OUD; how-tos for identifying
recovery support services; and how-tos for
locating medical and behavioral health service
providers who specialize in treating OUD or
other SUDs.
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